Ke Zhiyin, Liang Ailing, Liu Yongjun
Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.
Department of Biochemistry and Molecular Biology Guangdong Medical University, Dongguan 523808, China.
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):265-270. doi: 10.3779/j.issn.1009-3419.2021.101.09.
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer. .
肺癌是最常被诊断出的癌症，也是癌症死亡的主要原因。尽管在化疗、放疗和靶向治疗方面取得了巨大进展，但获得性耐药的出现阻碍了临床治疗的疗效。研究表明，肿瘤是一类细胞周期调控机制受损的疾病，其中检查点激酶（Chk）起核心作用，Chk1和Chk2是检查点中非常重要的蛋白激酶。近年来，发现Chk1和Chk2的调控在肺癌的临床治疗和耐药机制中起重要作用。本文综述了细胞周期检查点激酶与肺癌耐药的机制，并阐述了肺癌有效的治疗靶点和方法。
